Literature DB >> 16505288

Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis.

C Maesawa1, S Ogasawara, A Yashima-Abo, T Kimura, K Kotani, S Masuda, Y Nagata, T Iwaya, K Suzuki, T Oyake, Y Akiyama, H Kawamura, T Masuda.   

Abstract

OBJECTIVE: Aberrant expression of maspin protein related to DNA hypomethylation in the promoter region is frequently observed in gallbladder carcinomas, whereas the non-tumorous gallbladder epithelium is maspin negative. We investigated maspin expression in non-tumorous gallbladder epithelium in patients with cholelithiasis.
METHODS: An immunohistochemical study of maspin expression was performed in 69 patients with cholelithiasis and 30 patients with gastric cancer without cholelithiasis.
RESULTS: Immunoreactivity for maspin was observed in focal and patchy regions of the gallbladder epithelium. Positive immunoreactivity for maspin was significantly associated with the presence of intestinal metaplasia in patients with cholelithiasis (p<0.05).
CONCLUSION: The high incidence of aberrant maspin expression in both intestinal metaplasia and carcinoma of the gallbladder supports the assumption that intestinal metaplasia of the gallbladder may predispose to gallbladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505288      PMCID: PMC1860347          DOI: 10.1136/jcp.2005.027284

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Expression of the tumor suppressor gene Maspin in human pancreatic cancers.

Authors:  N Maass; T Hojo; M Ueding; J Lüttges; G Klöppel; W Jonat; K Nagasaki
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Epigenetic status and aberrant expression of the maspin gene in human hepato-biliary tract carcinomas.

Authors:  Kentaro Fujisawa; Chihaya Maesawa; Ryo Sato; Kei Wada; Satoshi Ogasawara; Yuji Akiyama; Masaru Takeda; Tomohiro Fujita; Koki Otsuka; Taro Higuchi; Kazuyuki Suzuki; Kazuyoshi Saito; Tomoyuki Masuda
Journal:  Lab Invest       Date:  2005-02       Impact factor: 5.662

3.  Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients.

Authors:  Yasuhito Yuasa; Hiromi Nagasaki; Yoshimitsu Akiyama; Hidekazu Sakai; Tomoko Nakajima; Yasuo Ohkura; Touichirou Takizawa; Morio Koike; Masao Tani; Takehisa Iwai; Kenichi Sugihara; Kazue Imai; Kei Nakachi
Journal:  Carcinogenesis       Date:  2004-10-21       Impact factor: 4.944

4.  Role for DNA methylation in the control of cell type specific maspin expression.

Authors:  Bernard W Futscher; Marc M Oshiro; Ryan J Wozniak; Nicholas Holtan; Christin L Hanigan; Hong Duan; Frederick E Domann
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

5.  Expression of homeodomain protein CDX2 in gallbladder carcinomas.

Authors:  Xiang-Song Wu; Yoshimitsu Akiyama; Toru Igari; Tohru Kawamura; Susumu Hiranuma; Toshikatsu Shibata; Kouji Tsuruta; Morio Koike; Shigeki Arii; Yasuhito Yuasa
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-11       Impact factor: 4.553

6.  The paradoxical expression of maspin in ovarian carcinoma.

Authors:  Anil K Sood; Mavis S Fletcher; Lynn M Gruman; Jeremy E Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy Arbour; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

7.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

8.  Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples.

Authors:  I Duarte; O Llanos; H Domke; C Harz; V Valdivieso
Journal:  Cancer       Date:  1993-09-15       Impact factor: 6.860

9.  Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.

Authors:  Satoshi Ogasawara; Chihaya Maesawa; Masahide Yamamoto; Yuji Akiyama; Kei Wada; Kentaro Fujisawa; Taro Higuchi; Yuki Tomisawa; Nobuhiro Sato; Shigeatsu Endo; Kazuyoshi Saito; Tomoyuki Masuda
Journal:  Oncogene       Date:  2004-02-05       Impact factor: 9.867

10.  Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis.

Authors:  Akira Ishikawa; Motoko Sasaki; Shusaku Ohira; Tetsuo Ohta; Koji Oda; Yuji Nimura; Miin-Fu Chen; Yi-Yin Jan; Ta-Sen Yeh; Yasuni Nakanuma
Journal:  Lab Invest       Date:  2004-05       Impact factor: 5.662

View more
  5 in total

1.  Incidental detection of carcinoma gall bladder in laparoscopic cholecystectomy specimens: a thirteen year study of 23 cases and literature review.

Authors:  Hanni V Gulwani; Suneeta Gupta; Sukhpreet Kaur
Journal:  Indian J Surg Oncol       Date:  2015-01-22

Review 2.  Maspin: the new frontier.

Authors:  Zhila Khalkhali-Ellis
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

3.  Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer.

Authors:  Jeong Kim; Kee-Taek Jang; Kap Hyun Kim; Jong Wook Park; Byung Jin Chang; Kwang Hyuck Lee; Jong Kyun Lee; Jin Seok Heo; Seong-Ho Choi; Dong Wook Choi; Jong Chul Rhee; Kyu Taek Lee
Journal:  Tumour Biol       Date:  2010-06-02

4.  Routine Histopathological Examination of the Specimen After Laparoscopic Cholecystectomy: Can We Be Brave Enough to Give Up?

Authors:  Ramazan Kozan; Safa Özaydın; Hüseyin Bayhan; Sezai Leventoğlu; Ahmet Karamercan; Ahmet Ziya Anadol; Mustafa Şare; Abdülkadir Bülent Aytaç
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

5.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.